Eton Pharmaceuticals, Inc. (ETON)
Market Cap | 84.27M |
Revenue (ttm) | 35.30M |
Net Income (ttm) | 913,000 |
Shares Out | 25.69M |
EPS (ttm) | 0.04 |
PE Ratio | 82.00 |
Forward PE | 64.94 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 18,659 |
Open | 3.340 |
Previous Close | 3.400 |
Day's Range | 3.250 - 3.400 |
52-Week Range | 2.420 - 5.810 |
Beta | 1.27 |
Analysts | Strong Buy |
Price Target | 9.00 (+174.39%) |
Earnings Date | Aug 8, 2024 |
About ETON
Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortison... [Read more]
Full Company ProfileFinancial Performance
In 2023, ETON's revenue was $32.64 million, an increase of 42.60% compared to the previous year's $22.89 million. Losses were -$936,000, -89.62% less than in 2022.
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for ETON stock is "Strong Buy." The 12-month stock price forecast is $9.0, which is an increase of 174.39% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/p/u/press9-2422471.jpg)
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a n...
![](https://cdn.snapi.dev/images/v1/e/k/conf14-2404147.jpg)
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases,...
![](https://cdn.snapi.dev/images/v1/j/u/press12-2399259.jpg)
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually -- Produ...
![](https://cdn.snapi.dev/images/v1/c/p/conf10-2398349.jpg)
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing ...
![](https://cdn.snapi.dev/images/v1/p/r/press18-2337237.jpg)
Relief Therapeutics Enters into Exclusive U.S. License and Supply Agreement with Eton Pharmaceuticals for PKU GOLIKE
GENEVA, SWITZERLAND / ACCESSWIRE / March 22, 2024 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) (Relief, or the Company), a biopharmaceutical company committed to delivering in...
![](https://cdn.snapi.dev/images/v1/p/b/press12-2336809.jpg)
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
DEER PARK, Ill., March 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...
![](https://cdn.snapi.dev/images/v1/r/w/press5-2325241.jpg)
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
DEER PARK, Ill., March 14, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...
![](https://cdn.snapi.dev/images/v1/j/8/conf9-2302226.jpg)
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on Thursday, March 14, 2024
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...
![](https://cdn.snapi.dev/images/v1/p/r/press12-2285474.jpg)
Eton Pharmaceuticals Awarded U.S. Patent for Proprietary Hydrocortisone Oral Liquid Formulation
DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatme...
![](https://cdn.snapi.dev/images/v1/r/2/press3-2257308.jpg)
Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Current Nitisinone market is estimated to exceed $50 million annually ---- Product is now availa...
![](https://cdn.snapi.dev/images/v1/n/2/press1-2150862.jpg)
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
DEER PARK, Ill., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
![](https://cdn.snapi.dev/images/v1/n/f/conf18-2127478.jpg)
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to add...
![](https://cdn.snapi.dev/images/v1/e/t/press10-2089014.jpg)
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
-- Expect Q1 2024 product launch ---- Nitisinone market estimated to be more than $50 million annually ---- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04, 2023...
![](https://cdn.snapi.dev/images/v1/t/7/conf18-2033721.jpg)
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...
![](https://cdn.snapi.dev/images/v1/h/1/press15-2018270.jpg)
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
DEER PARK, Ill., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tr...
![](https://cdn.snapi.dev/images/v1/r/k/conf7-1999854.jpg)
Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
DEER PARK, Ill., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare disease...
![](https://cdn.snapi.dev/images/v1/k/j/press4-1974902.jpg)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Eton Pharmaceuticals, Inc. - ETON
NEW YORK , July 17, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Eton Pharmaceuticals, Inc. ("Eton" or the "Company") (NASDAQ: ETON). Such investors are advis...
![](https://cdn.snapi.dev/images/v1/e/q/press7-1950953.jpg)
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
DEER PARK, Ill., June 28, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...
![](https://cdn.snapi.dev/images/v1/p/c/press7-1886142.jpg)
Eton Pharmaceuticals Reports First Quarter 2023 Financial Results
DEER PARK, Ill., May 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing tre...
![](https://cdn.snapi.dev/images/v1/i/e/press3-1881744.jpg)
Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Product is now available exclusively through Optime Care -- DEER PARK, Ill., May 10, 2023 (GLOBE...
![](https://cdn.snapi.dev/images/v1/d/e/conf6-1869509.jpg)
Eton Pharmaceuticals to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
DEER PARK, Ill., May 03, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases...
![](https://cdn.snapi.dev/images/v1/n/i/press18-1800954.jpg)
Eton Pharmaceuticals Reports Fourth Quarter 2022 Financial Results
DEER PARK, Ill., March 16, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing t...
![](https://cdn.snapi.dev/images/v1/j/n/press6-1797420.jpg)
Eton Pharmaceuticals Announces Acquisition of Rare Disease Product Candidate ET-600
-- Product is targeting rare pediatric endocrinology condition ---- Potential for NDA submission in Q2 2024 -- DEER PARK, Ill., March 15, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the ...
![](https://cdn.snapi.dev/images/v1/n/l/conf10-1786379.jpg)
Eton Pharmaceuticals to Report Fourth Quarter 2022 Financial Results on Thursday, March 16, 2023
DEER PARK, Ill., March 07, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseas...
![](https://cdn.snapi.dev/images/v1/i/r/press20-1703835.jpg)
Eton Pharmaceuticals Announces FDA Acceptance of NDA Response for Dehydrated Alcohol Injection
-- Product previously granted orphan drug designation for methanol poisoning ---- Application assigned a PDUFA date of June 27, 2023 -- DEER PARK, Ill., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Eton Pharmace...